Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | XAV939 |
Synonyms | |
Therapy Description |
XAV939 selectively inhibits Wnt/beta-catenin-mediated signaling by inhibiting tankyrase1/2, thus stabilizing axin and stimulating beta-catenin degradation (PMID: 19759537, PMID: 32681294). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
XAV939 | XAV-939 | Tankyrase Inhibitor 11 | XAV939 selectively inhibits Wnt/beta-catenin-mediated signaling by inhibiting tankyrase1/2, thus stabilizing axin and stimulating beta-catenin degradation (PMID: 19759537, PMID: 32681294). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
APC E853* APC T1556fs | colorectal cancer | resistant | XAV939 | Preclinical - Cell culture | Actionable | In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs (reported as APC T1556fs*3) demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481). | 28179481 |
APC S811* | colorectal cancer | sensitive | XAV939 | Preclinical - Cell culture | Actionable | In a preclinical study, XAV939 inhibited growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481). | 28179481 |
APC Q886* | colorectal cancer | predicted - resistant | XAV939 | Preclinical | Actionable | In a preclinical study, XAV939 treatment did not affect growth of mouse intestinal organoids expressing APC Q884* (corresponding to Q886* in human) in culture (PMID: 31337618). | 31337618 |
APC Q1406* | colorectal cancer | predicted - sensitive | XAV939 | Preclinical | Actionable | In a preclinical study, XAV939 treatment inhibited growth of mouse intestinal organoids expressing APC Q1045* (corresponding to Q1046* in human) in culture (PMID: 31337618). | 31337618 |
APC N1819fs APC wild-type | colorectal cancer | resistant | XAV939 | Preclinical - Cell culture | Actionable | In a preclinical study, a colorectal cancer cell line harboring APC N1819fs (reported as N1819fs*7) and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481). | 28179481 |
APC S1197* APC S1278* | colorectal cancer | sensitive | XAV939 | Preclinical - Cell culture | Actionable | In a preclinical study, XAV939 inhibited growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481). | 28179481 |
APC inact mut | colorectal cancer | sensitive | XAV939 | Preclinical | Actionable | In a preclinical study, XAV939 inhibited growth of colorectal cancer cells harboring APC inactivating mutations in culture (PMID: 19759537). | 19759537 |
APC L665* APC R1450* | colorectal cancer | sensitive | XAV939 | Preclinical - Cell culture | Actionable | In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481). | 28179481 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|